Jamjoom Pharmaceuticals Factory Co. announces its Interim Financial results for the Period Ending on 2024-09-30 ( Nine Months )
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 327.58 | 292.61 | 11.951 | 345.74 | -5.252 |
| Gross Profit (Loss) | 194.41 | 187.23 | 3.834 | 218.18 | -10.894 |
| Operational Profit (Loss) | 95.67 | 84.67 | 12.991 | 104.26 | -8.239 |
| Net profit (Loss) | 94.99 | 77.25 | 22.964 | 106.95 | -11.182 |
| Total Comprehensive Income | 93.41 | 76.43 | 22.216 | 106.73 | -12.48 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Sales/Revenue | 1,058.77 | 891.86 | 18.714 |
| Gross Profit (Loss) | 661.99 | 584.93 | 13.174 |
| Operational Profit (Loss) | 326.52 | 271.14 | 20.424 |
| Net profit (Loss) | 304.92 | 247.92 | 22.991 |
| Total Comprehensive Income | 257.3 | 215.04 | 19.652 |
| Total Shareholders Equity (after Deducting Minority Equity) | 1,444.54 | 1,361.3 | 6.114 |
| Profit (Loss) per Share | 4.36 | 3.54 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | Revenue for the current quarter has increased by 11.9% as compared to the same quarter of the last year mainly due to increase in sales volumes across key markets and therapeutic areas. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | Net profit for the current quarter increased by 23.0% as compared to the same quarter of last year mainly due to revenue growth, improved costs and operational efficiencies. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | Sales decreased by 5.3% as compared to 2Q 2024 due to expected fluctuation in quarterly sales. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | Net profit for the current quarter decreased by 11.2% as compared to the previous quarter, due to a decline in overall sales, and an increased contribution of sales from low margin markets and public tenders as compared to the previous quarter. |
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | Revenue for the current period has increased by 18.7% as compared to the same period of last year, this increase is primarily driven by volumetric growth across key markets and therapeutic areas, driven by successful execution of the Company’s strategy and supported by price increases and new brands. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | Net profit for the current period increased by 23.0% as compared to the same period of the last year mainly driven by revenue growth complemented by operating leverage from economies of scale, cost efficiencies and contribution from our investment in Algeria. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | None |
| Reclassification of Comparison Items | Certain figures for the prior period have been reclassified to conform to the presentation in the current period. |
| Additional Information | The Company’s financial position continued to be strong with zero debt.
As of 30 September 2024, the Company had a cash balance of SAR 119.0 million, which represented a decrease of 58.1% compared to the balance at December 31, 2023 mainly due to two dividend payouts to Shareholders in June and August 2024.
Please refer to the attached Press Release for more information. |
| Attached Documents |  |
Comments